Could a pill tame aggression in fragile x? new trial aims to find out
NCT ID NCT07328529
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether the drug SRX246 can reduce irritability, aggression, and self-injury in adult males with Fragile X syndrome. Eighty participants will take either SRX246 or a placebo daily for up to 8 months, with regular check-ins by phone or home visits. The goal is to see if the drug improves behavior and is safe to use.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SRX246 (a vasopressin 1a receptor antagonist)
What this could lead to
If it works, this could provide a new treatment option to reduce aggressive behaviors in people with Fragile X syndrome, improving daily life for them and their caregivers.
What could go wrong
This is an early Phase 2 trial with only 80 participants, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGGRESSIVE BEHAVIOR IN FRAGILE X SYNDOME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cincinnati Children's Hospital
Cincinnati, Ohio, 45229, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Rush University Medical Center
Chicago, Illinois, 60612, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of California, Davis, MIND Institute
Sacramento, California, 95817, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••